On Tuesday the UK became the latest country to jump back on the nuclear energy bandwagon. But 20 years after Chernobyl, how easy is it to turn on the nuclear tap?
Complying with the EU’s labyrinthine new REACH chemicals legislation was always going to be a tortuous process. For those who wait too long, it could be impossible.
This week the European Investment Fund took the first step in its ambitious new plan to unleash a wave of technology transfer across Europe. In doing so it endorsed a model pioneered in the UK.
French researchers have developed a cell therapy that could slash the risk of rejection after bone marrow grafts to under 5 per cent, and are looking for first-round funding.
The European Investment Fund has partnered with UK technology commercialisation company IP Group to form a venture capital fund to invest in university spin-outs.
For the last three years, the French parliament has been struggling with legislation on copyright and associated rights in information society. It has surfaced in the headlines, portrayed as a fight to force Apple to make its iTunes music downloads playable on competing music boxes. But there's more involved.
A key distinction between physical and intellectual property is that the value of the latter is created as much by sharing it as by owning it. How to share it, between creator and enabler, is a particularly acute issue within the academic environment - as indicated by a recent, noteworthy debate on the subject in Sweden.
Technology transfer is a sensitive and complex process. Changing one factor won’t provide the magic bullet, says Anna S. Nilsson, Science and Technology Attaché at the Swedish Embassy in Washington DC.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.